OncoMatch

OncoMatch/Clinical Trials/NCT05800587

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Is NCT05800587 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for lung cancer.

Phase 2RecruitingFox Chase Cancer CenterNCT05800587Data as of Jun 2026

Treatment: Carboplatin · Pemetrexed · Paclitaxel · Nab paclitaxel · Docetaxel · Gemcitabine · Etoposide · Irinotecan · Topotecan · LurbinectedinThis is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

CarboplatinPemetrexedPaclitaxelNab paclitaxelDocetaxelGemcitabineEtoposideIrinotecanTopotecanLurbinectedin

Cancer type

Non-Small Cell Lung Carcinoma

Small Cell Lung Cancer

Disease stage

Required: Stage IV, III (AJCC version 8)

stage IV (AJCC version 8) lung cancer (small cell or non-small cell). Patients with stage III disease who are not felt to be candidates for definitive therapy are also eligible.

Performance status

ECOG 0–3(Limited self-care)

Prior therapy

Cannot have received: targeted therapy (TKI, sotorasib)

Exception: if not combined with a cytotoxic agent

Patients receiving only a targeted agent (e.g. TKI, sotorasib etc.) or immunotherapy without a cytotoxic agent

Cannot have received: immunotherapy

Exception: if not combined with a cytotoxic agent

Patients receiving only a targeted agent (e.g. TKI, sotorasib etc.) or immunotherapy without a cytotoxic agent

Cannot have received: investigational agent

Patients currently receiving investigational agents for cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Fox Chase Cancer Center · Philadelphia, Pennsylvania

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT05800587 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior targeted therapy, immunotherapy, investigational agent disqualifies patients from enrollment.

What disease stage is eligible?

Stage IV or III is required.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify